31.48

0.06% -0.0184

Catalyst Pharmaceuticals Inc (CPRX)

Overview News Price History Option Chain Financials Why CPRX Down? Discussions Forecast

Catalyst Pharmaceuticals Inc stock is traded at $31.48, with a volume of 272.14K. It is down -0.06% in the last 24 hours and up +0.68% over the past month. Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.

Previous Close:

$31.50

Open:

$31.49

24h Volume:

272.14K

Relative Volume:

0.12

Market Cap:

$3.85B

Revenue:

$596.96M

Net Income/Loss:

$221.32M

P/E Ratio:

18.10

EPS:

1.7397

Net Cash Flow:

$208.13M

1W Performance:

+0.16%

1M Performance:

+0.68%

6M Performance:

+38.56%

1Y Performance:

+50.27%

1-Day Range:

$31.48

$31.50

1-Week Range:

$31.43

$31.50

52-Week Range:

$19.05

$32.56

Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile

Name

Catalyst Pharmaceuticals Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(305) 529-2522

Address

355 ALHAMBRA CIRCLE, CORAL GABLES

Employee

182

Twitter

@CatalystForRare

Next Earnings Date

2026-08-05

Latest SEC Filings

CPRX's Discussions on Twitter

Compare CPRX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CPRX Catalyst Pharmaceuticals Inc	31.48	3.85B	596.96M	221.32M	208.13M	1.7397
VRTX Vertex Pharmaceuticals Inc	525.36	134.02B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.19	68.59B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	920.80	58.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	320.31	41.76B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	192.01	40.23B	742.00K	-1.37B	-1.07B	-7.0731

Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-04-25	Initiated	Robert W. Baird	Outperform
Nov-18-24	Initiated	Stephens	Overweight
Mar-14-24	Initiated	Citigroup	Buy
Mar-07-24	Initiated	BofA Securities	Buy
Dec-21-23	Initiated	Oppenheimer	Outperform
Aug-24-22	Downgrade	ROTH Capital	Buy → Neutral
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Sep-07-18	Resumed	Piper Jaffray	Overweight
Oct-05-16	Upgrade	Piper Jaffray	Neutral → Overweight
Apr-26-16	Downgrade	Piper Jaffray	Overweight → Neutral
Sep-30-14	Reiterated	ROTH Capital	Buy
Sep-16-14	Reiterated	ROTH Capital	Buy
Sep-15-14	Reiterated	H.C. Wainwright	Buy
Oct-21-13	Reiterated	Aegis Capital	Buy
Sep-24-13	Initiated	Maxim Group	Buy
Sep-06-13	Reiterated	Aegis Capital	Buy
Apr-18-13	Initiated	Aegis Capital	Buy
Aug-27-12	Upgrade	Rodman & Renshaw	Mkt Perform → Mkt Outperform
Oct-01-09	Upgrade	Merriman	Sell → Neutral
May-29-09	Downgrade	Hapoalim	Neutral → Underperform
May-29-09	Downgrade	Merriman Curhan Ford	Buy → Sell
Dec-15-08	Initiated	Merriman Curhan Ford	Buy
Nov-28-07	Initiated	Rodman & Renshaw	Mkt Outperform
Jan-31-07	Initiated	Stifel Nicolaus	Buy
Jan-05-07	Initiated	First Albany	Buy

View All

Catalyst Pharmaceuticals Inc Stock (CPRX) Latest News

Jul 05, 2026

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1bn - Investing.com

Jul 05, 2026

Jul 02, 2026

CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data - TradingView

Jul 02, 2026

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX): A Deep Value Play with Rare Disease Pipeline Strength - ChartMill

Jul 02, 2026

Jul 01, 2026

CPRXCatalyst Pharmaceuticals Inc Earnings - Finviz

Jul 01, 2026

Santhera Notes Topline Results from Catalyst Pharmaceuticals’ Phase 1 Clinical Study of AGAMREE® - Yahoo Finance

Jul 01, 2026

Jun 30, 2026

Vamorolone Phase 1 results at Catalyst (NASDAQ: CPRX) show activity without key immunosuppression - Stock Titan

Jun 30, 2026

Catalyst reports Phase 1 vamorolone study results - Investing.com

Jun 30, 2026

Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses - The Manila Times

Jun 30, 2026

Catalyst's rare-disease steroid showed immune activity without the usual suppression - Stock Titan

Jun 30, 2026

Jun 29, 2026

Monolithic Power Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Monolithic Power Systems, Inc.MPWR - Business Wire

Jun 29, 2026

Skeletal Nickel Catalyst Market Growth to Accelerate by 2035 Amid Rising Pharma DemandNews and Statistics - IndexBox

Jun 29, 2026

Jun 28, 2026

Acadia Pharmaceuticals (ACAD) Gets 90-Day Catalyst Watch from Ci - GuruFocus

Jun 28, 2026

Quantified Common Ground Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus

Jun 28, 2026

Jun 27, 2026

Catalyst Pharmaceuticals (CPRX) Following Strong Rare Disease Results Is The Upside Already Priced In - Sahm

Jun 27, 2026

Jun 26, 2026

Shuttle Pharmaceuticals (NASDAQ:SHPH) surges; Dogecoin miner news sends volume up 70x - TechStock²

Jun 26, 2026

Price to earnings forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Price to sales forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Enterprise value to revenue forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Price to book forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Enterprise value to EBIT forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of Catalyst Pharmaceuticals, Inc. – NASDAQ:CPRX - TradingView

Jun 26, 2026

Jun 25, 2026

Understanding the Setup: (CPRX) and Scalable Risk - Stock Traders Daily

Jun 25, 2026

Catalyst Pharmaceuticals (CPRX) Short Interest & Short Float | Updated Jun 2026 - MarketBeat

Jun 25, 2026

Nationwide Renaissance Small Cap Growth Fund's Catalyst Pharmaceuticals Inc(CPRX) Holding History - GuruFocus

Jun 25, 2026

Jun 24, 2026

Catalyst Pharmaceuticals stock edges higher to 31.41 after patient summit event, CatalystForRare - Traders Union

Jun 24, 2026

Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - Business Wire

Jun 24, 2026

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Passes "Caviar Cruise" Quality Screen with Zero Debt and 147.5% ROIC - ChartMill

Jun 24, 2026

Catalyst Pharmaceuticals (CPRX) Gets Early FTC Clearance For Angelini Merger - Sahm

Jun 24, 2026

Jun 23, 2026

Catalyst Pharmaceuticals to Be Acquired by Angelini Pharma in All-Cash Merger – Key Details from 8-K Filing - Minichart

Jun 23, 2026

Catalyst Pharma Gains FTC Clearance for Angelini Merger - TipRanks

Jun 23, 2026

Catalyst Pharmaceuticals merger cleared HSR waiting period as closing targets Q3 2026 - TradingView

Jun 23, 2026

HSR waiting period ends for Catalyst (NASDAQ: CPRX) and Angelini Pharma merger - Stock Titan

Jun 23, 2026

Jun 22, 2026

Catalyst Pharmaceuticals consensus steadies, Hold rating frames CPRX shares - AD HOC NEWS

Jun 22, 2026